About this trial
Eligible patients will be interviewed by research staff to explain the trial design and rationale. Written informed consent will be obtained from patients who voluntarily agree to participate. Demographics and medical history will be obtained. A 12-lead ECG will be performed; it has not been performed within 6 months. A photo of the 12-lead ECG will be taken by research staff using the DigitHeart-2 smartphone application. Predictions from DigitHeart-2/MERL-ECHO and other machine learning models hosted by the investigator team for each of the target anatomical and mechanical properties will be recorded. The cardiologist in charge of the patient, who is blinded to the prediction results from DigitHeart-2/MERL-ECHO, will perform echocardiography according to American Society of Echocardiography guidelines, which will serve as the gold standard for accuracy evaluation.
Eligibility criteria
Qualifiers
aged ≥ 18 years old
planned to have echocardiography performed
voluntarily agree to participate in the trial.
Disqualifiers
had echocardiography performed within 1 month
pacemaker rhythm on ECG
dextrocardia
complex adult congenital heart disease
Trial design
Treatments tested in this trial
- echocardiography
Treatment groups
Locations
1Sponsors and collaborators
The University of Hong Kong
Lead sponsor